Therefore, it would be interesting to determine if this missense SNP generates a form of LMTK2 with differential binding capacity for myosin VI, ultimately affecting intracellular trafficking and the endosomal secretory pathway in prostate cancers. This evidence concerns the gene LMTK2 and prostate carcinoma.